PEGDE-Crosslinked Hyaluronic Acid Fillers With Lower Epoxide Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hyaluronic acid-based dermal fillers using 1,4-butanediol diglycidyl ether (BDDE) as a crosslinker contain toxic epoxide impurities and lack variability in properties, necessitating laborious purification and limiting the ability to tailor formulations for specific cosmetic needs.
Innovation Solution
Employing high and low molecular weight polyethylene glycol diglycidyl ether (PEGDE) as crosslinkers to create HA-based dermal fillers with improved safety and balanced rheological properties, allowing for tailored product characteristics through varying molecular weights and reduced toxic epoxide groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BDDE is used as crosslinker for HA-based dermal fillers, then the fillers achieve stable three-dimensional network structure and improved in vivo longevity, but toxic epoxide impurities are generated requiring laborious purification
Solution Approach 1:
The patent changes the molecular weight parameter of the PEGDE crosslinker from conventional low molecular weight (BDDE) to high molecular weight (2000-10000 Da), which fundamentally alters the reaction characteristics and eliminates toxic epoxide impurities while maintaining crosslinking effectiveness
Solution Approach 2:
The patent introduces PEGDE as an intermediary crosslinking agent that mediates the crosslinking reaction between HA molecules, providing a safer alternative to BDDE that reduces toxic impurities while achieving the desired gel structure
2Stability of the object's composition
If BDDE is used as crosslinker, then crosslinked HA gels achieve stable structure, but the properties of final gel product lack variability and cannot be tailored for specific cosmetic needs
Solution Approach 1:
The patent utilizes the variable molecular weight parameter of PEGDE (ranging from 2000 to 10000 Da) to create a series of crosslinkers with different properties, enabling tailored gel formulations for specific cosmetic applications while maintaining structural stability
Solution Approach 2:
The patent applies different molecular weight PEGDE variants to different formulation requirements, allowing optimization of specific gel properties (cohesivity, elasticity, degradation rate) for different cosmetic indications
3Object-affected harmful factors
If high molecular weight PEGDE is used as crosslinker, then toxic epoxide groups are reduced and safety is improved, but the ability to influence gel properties via crosslinker amount is limited
Solution Approach 1:
The patent compensates for the reduced property-tuning flexibility of HMW-PEGDE by systematically varying its concentration in the formulation, demonstrating that safe and effective gel properties can be achieved through optimization of crosslinker amount rather than molecular weight
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of PEGDE enables the production of stable, thermally resistant HA gels with customizable properties, such as elasticity and cohesivity, suitable for cosmetic applications, while minimizing toxic impurities and enhancing injectability.
Implementation Method 1
the epoxide groups of BDDE preferentially react with the primary hydroxyl group of HA to form stable ether bonds
Implementation Method 2
HMW-PEGDE results in crosslinked HA gels that are highly stable against thermal degradation, such as the thermal degradation encountered during autoclaving
Data Source
Figure 1
AI summary
The present invention relates to a dermal filler composition based on crosslinked hyaluronic acid, wherein the hyaluronic acid is crosslinked with a high molecular weight polyethylene glycol diglycidyl ether (PEGDE) crosslinker having an average number of -CH2-CH2-O- repetitive units of 8 to 90. Furthermore, the present invention relates to a method for preparing said dermal filler composition and its use for cosmetic purposes.